New Delhi (NVI): Pharma giant Serum Institute of India (SII), is hopeful of launching Covovax by June, developed in partnership with US-based vaccine developer Novavax, its CEO Adar Poonawalla said today.
The US-based pharma firm’s Covid jab was found to be 89.3 per cent effective in a UK trial.
The chief of Serum Institute of India, Adar Poonawalla, today announced that the company is looking forward to launch a second coronavirus vaccine.
“Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!” Adar Poonawalla tweeted this afternoon,” Poonawalla’s tweet read.
Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!
— Adar Poonawalla (@adarpoonawalla) January 30, 2021
The Pune-based Serum Institute has already applied for local trials for the vaccine candidate in India.
On January 16, India began a nation-wide inoculation drive after the drug regulator DCGI approved two vaccines – the SII’s Covishield and Bharat Biotech’s Covaxin for emergency use.
Covishield has been developed in partnership with the Oxford University and British-Swedish firm AstraZeneca.
-CHK
